Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy

NCT04058028 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04058028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04058028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
February 19, 2020
Completion date
July 25, 2023
Enrollment
244 (actual)
Sites
147

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)